Canton Strategic Holdings (CNTN) Net Income towards Common Stockholders (2021 - 2026)

Canton Strategic Holdings (CNTN) reported Net Income towards Common Stockholders of -$47.3 million for Q1 2026, down 1762.66% on a YoY basis from $2.8 million in Q1 2025, and down 1939.47% quarter-over-quarter from -$2.3 million in Q4 2025.

Canton Strategic Holdings (CNTN) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends

Canton Strategic Holdings has reported Net Income towards Common Stockholders for 6 years, with the latest figure at -$47.3 million in Q1 2026.

  • For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 1762.66% year-over-year to -$47.3 million; the trailing twelve-month figure through Mar 2026 stood at -$53.6 million (down 330.72% YoY), and the FY2025 full-year result was -$35.9 million, down 194.45% from the prior year.
  • Net Income towards Common Stockholders for Q1 2026 stood at -$47.3 million, down from -$2.3 million in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was -$1.6 million in Q2 2022, with the low at -$47.3 million in Q1 2026.
  • Historically, Net Income towards Common Stockholders has averaged -$5.1 million across 5 years, with a median of -$2.3 million in 2024.
  • Annual changes were most pronounced in 2025 — Net Income towards Common Stockholders soared 44.63% — and 2026, when it slumped 1762.66%.
  • Canton Strategic Holdings' Net Income towards Common Stockholders stood at -$1.8 million in 2022, then tumbled by 40.74% to -$2.5 million in 2023, then slumped by 53.08% to -$3.8 million in 2024, then jumped by 38.7% to -$2.3 million in 2025, then plunged by 1939.47% to -$47.3 million in 2026.
  • The last three Net Income towards Common Stockholders figures came in at -$47.3 million (Q1 2026), -$2.3 million (Q4 2025), and -$2.1 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -26.94 Mn
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -13.56 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 2.50 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -3.63 Mn
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -14.46 Mn
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -1.50 Mn
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 1.03 Bn
9 Abivax 91.96 Bn 91.96 Bn - -56.48 Mn
10 Canton Strategic Holdings 699.97 Mn 658.44 Mn - -47.34 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -47.34 Mn
Dec 31, 2025 -2.32 Mn
Sep 30, 2025 -2.10 Mn
Jun 30, 2025 -1.86 Mn
Mar 31, 2025 -2.54 Mn
Dec 31, 2024 -3.79 Mn
Sep 30, 2024 -3.80 Mn
Jun 30, 2024 -2.33 Mn
Mar 31, 2024 -2.26 Mn
Dec 31, 2023 -2.47 Mn
Sep 30, 2023 -1.82 Mn
Jun 30, 2023 -2.34 Mn
Mar 31, 2023 -2.69 Mn
Dec 31, 2022 -1.76 Mn
Sep 30, 2022 -2.13 Mn
Jun 30, 2022 -1.64 Mn
Mar 31, 2022 -2.95 Mn
Dec 31, 2021 -359,593.00
Sep 30, 2021 -777,113.00
Jun 30, 2021 -1.29 Mn